In June, the Food and Drug Administration will decide whether to grant full approval to Biogen and Eisai’s anti-amyloid Alzheimer’s drug Leqembi (generic name…
A second patient has died of brain bleeds — an anti-amyloid side effect — during the clinical trial extension of Eisai’s Alzheimer’s treatment lecanemab…
To speed up the search for Alzheimer’s treatments and cures, researchers have built machine learning technology to identify existing drugs that could be repurposed…
We talked with Banner Alzheimer’s Institute Director Pierre Tariot about the most recent results from Eli Lilly’s Alzheimer’s trial for donanemab — what he…
In yet another encouraging step toward the development of what could be the first drug approved for Alzheimer’s disease, the Federal Drug Administration today…
While most Alzheimer’s detection and prevention research is focused on the aggregation of tau tangles and amyloid beta proteins in the brain, some novel…
The latest news about Biogen’s controversial Alzheimer’s drug popped into my email at 8:26 a.m. last Wednesday. Coincidentally it arrived just as I was…
Hours feel like days. Days feel like months. And months? Well they can feel like a decade. Particularly when you are awaiting the restart…
An experimental “seaweed” drug called Oligomannate, which treats Alzheimer’s, is now available for patients to buy in China. Chinese officials announced conditional approval to…
Reporting on a procedure performed last year, scientists at the West Virginia University Rockefeller Neuroscience Institute said today that using low-intensity focused ultrasound is…